Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-α antibody

被引：22

作者：

Wollina, U

Konrad, H

机构：

[1] Dept Dermatol Dresden Friedrichstadt, D-01067 Dresden, Germany

[2] Univ Jena, Dept Dermatol & Allergol, D-07740 Jena, Germany

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2002年 / 16卷 / 02期

关键词：

infliximab; psoriatic arthritis; tumour necrosis factor-alpha;

D O I：

10.1046/j.1468-3083.2002.00391.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Currently available treatments for psoriatic arthritis are either not completely effective or toxic in some patients. As tumour necrosis factor (TNF)-alpha is involved in both the joint and skin involvement in psoriatic arthritis, blockade of TNF-alpha seems a reliable way to treat patients with this disease. We report two patients with progressive recalcitrant psoriatic arthritis treated with low-dose methotrexate (7.5 mg, once per week) in combination with intravenous chimeric monoclonal anti-TNF-alpha antibody (infliximab, 3 mg/kg body weight). Both showed a dramatic and rapid response in the reduction of pain, followed by improvement of laboratory and clinical signs of joint inflammation. Skin disease also responds after a short delay. The observation shows that infliximab is effective and well tolerated in patients with recalcitrant progressive psoriatic arthritis. Different kinetics of symptom release during treatment suggest a variable role for TNF-a in disease pathways of pain, joint inflammation and skin involvement.

引用

页码：127 / 129

页数：3

共 26 条

[1] Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermis [J].